Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus

Arthritis Care and Research

Volumn 70, Issue 1, 2018, Pages 125-133

  Nantes, Stephanie G ^a   Strand, Vibeke ^b   Su, Jiandong ^a   Touma, Zahi ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONSTRUCT VALIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LUPUS QUALITY OF LIFE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; QUESTIONNAIRE; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; DISEASE EXACERBATION; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PSYCHOLOGY; QUALITY OF LIFE; REPRODUCIBILITY; TIME FACTOR; VALIDATION STUDY;

DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 85038112161     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23240     Document Type: Article

References (28)

1. Panopalis P, Clarke AE. Quality of life in systemic lupus erythematosus. Clin Dev Immunol 2006;13:321–4.
2. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972–9.
3. McHorney CA, Ware JE Jr., Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40–66.
4. Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36: its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608–14.
5. Kuriya B, Gladman DD, Ibañez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008;59:181–5.
6. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005;32:1706–8.
7. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
8. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV Outcome Measures in Rheumatology. Lupus 2000;9:322–7.
9. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol 2011;38:1898–905.
10. McElhone K, Abbott J, Sutton C, Mullen M, Lanyon P, Rahman A, et al. Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2016;68:1505–13.
11. Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford) 2015;54:940–9.
12. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005;5:317–26.
13. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67–70.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
15. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000;38:115–21.
16. Touma Z, Gladman DD, Ibañez D, Urowitz MB. A signal of improvement in lupus disease activity at 3 months predicts further valid improvement at 6 months [abstract]. Arthritis Rheum 2014;Suppl 66:S1152–3.
17. Choi CB, Liang MH, Bae SC. Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Res Ther 2016;18:1.
18. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The use of the Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011;50:982–8.
19. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001;54:1204–17.
20. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490–7.
21. Fernández M, Alarcón GS, McGwin G Jr., Sanchez ML, Apte M, Vilá LM, et al. Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis Rheum 2007;57:986–92.
22. Fortin PR, Abrahamowicz M, Neville C, du Berger R, Fraenkel L, Clarke AE, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998;7:101–7.
23. Strand V, Aranow C, Cardiel MH, Alarcon-Segovia D, Furie R, Sherrer Y, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677–86.
24. Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW, et al. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med 2014;1:e000031.
25. Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol 1997;24:2145–8.
26. Kiani AN, Strand V, Fang H, Jaranilla J, Petri M. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2013;52:1651–7.
27. Puhan MA, Guyatt GH, Montori VM, Bhandari M, Devereaux PJ, Griffith L, et al. The standard gamble demonstrated lower reliability than the feeling thermometer. J Clin Epidemiol 2005;58:458–65.
28. Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2010. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.